Indivior PLC
IZQVF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.01B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $3.01 Billion |
|---|---|
| Enterprise Value | $3.33 Billion |
| Annual dividend | $0.64 |
| Earnings per Share | $- |
| Beta | -0.06 |
| Outstanding Shares | - |
Return
| Return on Equity | -216.83% |
|---|---|
| Return on Assets | 36.58% |
| Return on Invested Capital | 156.16% |
Valuation & Multiples
| P/E Ratio | 9.66 |
|---|---|
| PEG | 4.27 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.42 |
| Enterprise Value to EBIT | 5.84 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | -2.59 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Indivior Plc
CEO: Shaun Thaxter
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, ...